SAN FRANCISCO, Oct. 23, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), today announced the dosing of the first patient in the LAPIS Phase 3 clinical study of pamrevlumab in patients with unresectable locally advanced pancreatic cancer (LAPC).
SAN FRANCISCO, Aug. 01, 2019 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN), today announced that it will report second quarter 2019 financial results on Thursday, August 8, 2019 after market close, and will host a conference call to discuss finan… […]
FibroGen Receives One of China Pharmaceutical Industry’s Highest Awards for Clinical Innovation for Roxadustat
SAN FRANCISCO, Sept. 30, 2019 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN) today announced that roxadustat received the 2019 Dushu Lake Prize 独墅湖杯in China for “On-Market Innovative Drug with Highest Clinical Value.” The award was received by it… […]
FibroGen to Present Interim Phase 2 Data on Pamrevlumab in Subjects with Duchenne Muscular Dystrophy at the Parent Project Muscular Dystrophy 2019 Annual Conference
SAN FRANCISCO, June 28, 2019 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN), today announced that the company will present interim data on their open-label, single-arm Phase 2 trial evaluating pamrevlumab, a monoclonal antibody to connective tissu… […]